Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) Operating Expenses (2019 - 2026)

Biodesix filings provide 8 years of Operating Expenses readings, the most recent being $31.8 million for Q1 2026.

  • On a quarterly basis, Operating Expenses rose 17.21% to $31.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $92.2 million, a 40.59% decrease, with the full-year FY2025 number at $6.7 million, down 93.69% from a year prior.
  • Operating Expenses hit $31.8 million in Q1 2026 for Biodesix, up from $1.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $100.6 million in Q4 2024 to a low of $1.4 million in Q3 2024.
  • Median Operating Expenses over the past 5 years was $22.8 million (2023), compared with a mean of $25.2 million.
  • The widest YoY moves for Operating Expenses: up 1942.45% in 2025, down 98.08% in 2025.
  • Biodesix's Operating Expenses stood at $23.5 million in 2022, then fell by 8.34% to $21.5 million in 2023, then soared by 367.13% to $100.6 million in 2024, then plummeted by 98.08% to $1.9 million in 2025, then surged by 1543.69% to $31.8 million in 2026.
  • The last three reported values for Operating Expenses were $31.8 million (Q1 2026), $1.9 million (Q4 2025), and $28.8 million (Q3 2025) per Business Quant data.